Daiichi Sankyo and Merck withdrew an antibody-drug conjugate (ADC) filing for lung cancer after the FDA pushed back over an accelerated-approval evidentiary gap in the targeted population. The move underscores how quickly ADC programs can lose momentum when submissions don’t meet the agency’s threshold for the specific label pathway sought.